TIPS、静脉栓塞、逆行性经静脉栓塞治疗曲张出血实践指南2023

往期推荐（滑动查看）

9. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992;16:1343–9. 10. Saad WEA. Vascular anatomy and the morphologic and hemodynamic classifications of gastric varices and spontaneous portosystemic shunts relevant to the BRTO procedure. Tech Vasc Interv Radiol. 2013;16:60–100. 11. Kiyosue H, Mori H, Matsumoto S, Yamada Y, Hori Y, Okino Y. Transcatheter obliteration of gastric varices. Part 1. Anatomic classification. Radiographics. 2003;23:911–20. 12. Hirota S, Matsumoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices. Radiology. 1999; 211:349–56. 13. Matsumoto A, Hamamoto N, Nomura T, Hongou Y, Arisaka Y, Morikawa H, et al. Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices. Am J Gastroenterol. 1999;94:643–9. 14. Busk TM, Bendtsen F, Poulsen JH, Clemmesen JO, Larsen FS, Goetze JP, et al. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2018;314:G275–86. 15. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut. 1999;44:743–8. 16. Triantafyllou T, Aggarwal P, Gupta E, Svetanoff WJ, Bhirud DP, Singhal S. Polytetrafluoroethylene-covered stent graft versus bare stent in transjugular intrahepatic portosystemic shunt: systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A. 2018;28:867–79. 17. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LA, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73:366–413. 18. Luo X, Wang X, Zhu Y, Xi X, Zhao Y, Yang J, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm. Cardiovasc Intervent Radiol. 2019;42:737–43. 19. Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67:508–16. 20. Liu J, Ma J, Zhou C, Yang C, Huang S, Shi Q, et al. Potential benefits of underdilation of 8-mm covered stent in transjugular intrahepatic portosystemic shunt creation. Clin Transl Gastroenterol. 2021;12:e00376. 21. Trebicka J, Bastgen D, Byrtus J, Praktiknjo M, Terstiegen S, Meyer C, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival. Clin Gastroenterol Hepatol. 2019;17: 2793–99e1. 22. Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, et al. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep. 2021;3:100264. 23. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. on behalf of the Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022; 76:959–74. 24. Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, et al. on behalf of the Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practicebased recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol. 2022;20:1636–62e36. 25. La Mura V, Abraldes JG, Berzigotti A, Erice E, Flores-Arroyo A, García-Pagán JC, et al. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinicalhemodynamic correlation study. Hepatology. 2010;51:2108–16. 26. Silva-Junior G, Turon F, Baiges A, Cerda E, García-Criado Á, Blasi A, et al. Timing affects measurement of portal pressure gradient after placement of transjugular intrahepatic portosystemic shunts in patients with portal hypertension. Gastroenterology. 2017;152:1358–65. 27. Casado M, Bosch J, García-Pagán JC, Bru C, Bañares R, Bandi JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114:1296–303. 28. Rössle M, Haag K, Ochs A, Sellinger M, Nöldge G, Pararnau JM, et al. The transjugular intrahepatic portosystemic stentshunt procedure for variceal bleeding. N Engl J Med. 1994;330: 165–71. 29. Bellis L, Moitinho E, Abraldes JG, Graupera M, García-Pagán JC, Rodés J, et al. Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Gut. 2003;52:130–3. 30. Brensing KA, Hörsch M, Textor J, Schiedermaier P, Raab P, Schepke M, et al. Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt. Scand J Gastroenterol. 2002;37:1070–6. 31. Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: technical considerations. Tech Vasc Interv Radiol. 2016;19: 52–60. 32. Luo J, Li M, Zhang Y, Wang H, Huang M, Li Z, et al. Percutaneous transhepatic intrahepatic portosystemic shunt for variceal bleeding with chronic portal vein occlusion after splenectomy. Eur Radiol. 2018;28:3661–8. 33. Rodrigues SG, Sixt S, Abraldes JG, De Gottardi A, Klinger C, Bosch J, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019;49:20–30. 34. Zhang JB, Chen J, Zhou J, Wang X-M, Chen S, Chu J-G, et al. Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis. World J Clin Cases. 2021;9:5179–90. 35. Qi X, He C, Guo W, Yin Z, Wang J, Wang Z, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. Liver Int. 2016;36:667–76. 36. Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol. 2017;28:1714–21.e2. 37. Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial. Hepatology. 2022;76:676–88. 38. Qi X, Liu L, Bai M, Chen H, Wang J, Yang Z, et al. Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding: a meta-analysis. J Gastroenterol Hepatol. 2014;29:688–9640. Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, et al. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7:736–46. 41. Saab S, Kim NG, Lee EW. Practical tips on TIPS: when and when not to request it. Am J Gastroenterol. 2020;115:797–800. 42. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71. 43. D’Amico G, Maruzzelli L, Airoldi A, Petridis I, Tosetti G, Rampoldi A, et al. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. J Hepatol. 2021;75:1355–66. 44. Vizzutti F, Celsa C, Calvaruso V, Enea M, Battaglia S, Turco L, et al. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: a validated prediction model. Hepatology. 2023;77:476–88. 45. Yin X, Gu L, Zhang M, Yin Q, Xiao J, Wang Y, et al. Covered TIPS procedure-related major complications: incidence, management and outcome from a single center. Front Med. 2022;9: 834106. 46. Schultheiss M, Bettinger D, Sturm L, Schmidt A, Backhus J, Waidmann O, et al. Comparison of the covered self-expandable Viatorr CX stent with the covered balloon-expandable BeGraft peripheral stent for transjugular intrahepatic portosystemic shunt (TIPS) creation: a single-centre retrospective study in patients with variceal bleeding. CardioVasc Intervent Radiol. 2022;45:542–9. 47. Rössle M. TIPS: 25 years later. J Hepatol. 2013;59:1081–93. 48. Gaba RC, Khiatani VL, Knuttinen MG, Omene BO, Carrillo TC, Bui JT, et al. Comprehensive review of TIPS technical complications and how to avoid them. AJR Am J Roentgenol. 2011;196:675–85. 49. Bureau C, Thabut D, Jezequel C, Archambeaud I, D’Alteroche L, Dharancy S, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174:633–40. 50. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46. 51. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9. 52. Schindler P, Heinzow H, Trebicka J, Wildgruber M. Shuntinduced hepatic encephalopathy in TIPS: current approaches and clinical challenges. J Clin Med. 2020;9:3784. 53. Pereira K, Carrion AF, Martin P, Vaheesan K, Salsamendi J, Doshi M, et al. Current diagnosis and management of posttransjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int. 2015;35:2487–94. 54. Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149:660–8e1. 55. Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, et al. AVB-TIPS Study Group. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:587–98. 56. Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse algorithm. Hepatology. 2019;70:1928–41. 57. Wannhoff A, Hippchen T, Weiss CS, Friedrich K, Rupp C, Neumann-Haefelin C, et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. Aliment Pharmacol Ther. 2016;43:955–65. 58. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75. 59. Luo X, Zhao M, Wang X, Jiang M, Yu J, Li X, et al. Long-term patency and clinical outcome of the transjugular intrahepatic portosystemic shunt using the expanded polytetrafluoroethylene stent-graft. PloS One. 2019;14:e0212658. 60. McNaughton DA, Abu-Yousef MM. Doppler US of the liver made simple. Radiographics. 2011;31:161–88. 61. Abraldes JG, Gilabert R, Turnes J, Nicolau C, Berzigotti A, Aponte J, et al. Utility of color Doppler ultrasonography predicting tips dysfunction. Am J Gastroenterol. 2005;100: 2696–701. 62. Brants L, Leiderman M, Veitsman E, Ofer A, Beck-Razi N. Role of Doppler ultrasound combined with clinical features in the diagnosis of transjugular intrahepatic portosystemic shunt dysfunction in the era of covered stents. J Ultrasound Med. 2020;39:2373–7. 63. Olson E, Yune HY, Klatte EC. Transrenal-vein reflux ethanol sclerosis of gastroesophageal varices. AJR Am J Roentgenol. 1984;143:627–8. 64. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996;11:51–8. 65. Sabri SS, Swee W, Turba UC, Saad WEA, Park AW, Al-Osaimi AM, et al. Bleeding gastric varices obliteration with balloonoccluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol. 2011;22:309–16; quiz 316. 66. Gwon DI, Ko G-Y, Yoon H-K, Sung K-B, Kim JH, Shin JH, et al. Gastric varices and hepatic encephalopathy: treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration–a primary report. Radiology. 2013;268: 281–7. 67. Lee EW, Saab S, Gomes AS, Busuttil R, McWilliams J, Durazo F, et al. Coil-assisted retrograde transvenous obliteration (CARTO) for the treatment of portal hypertensive variceal bleeding: preliminary results. Clin Transl Gastroenterol. 2014;5: e61. 68. Park JK, Saab S, Kee ST, Busuttil RW, Kim HJ, Durazo F, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: review and meta-analysis. Dig Dis Sci. 2015;60:1543–53. 69. Fukuda T, Hirota S, Sugimura K. Long-term results of balloonoccluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol. 2001;12:327–36. 70. Lee EW, So N, Chapman R, et al. Usefulness of intraprocedural cone-beam computed tomography in modified balloon-occluded retrograde transvenous obliteration of gastric varices. World J Radiol. 2016;8:390–6. 71. Saad WEA, Sabri SS. Balloon-occluded retrograde transvenous obliteration (BRTO): technical results and outcomes. Semin Intervent Radiol. 2011;28:333–8.72. Tanihata H, Minamiguchi H, Sato M, Kawai N, Sonomura T, Takasaka I, et al. Changes in portal systemic pressure gradient after balloon-occluded retrograde transvenous obliteration of gastric varices and aggravation of esophageal varices. Cardiovasc Intervent Radiol. 2009;32:1209–16. 73. Patel M, Molvar C. Evolution of retrograde transvenous obliteration techniques. Semin Interv Radiol. 2018;35: 185–93. 74. Saad WE, Wagner CC, Lippert A, Al-Osaimi A, Davies MG, Matsumoto AH, et al. Protective value of TIPS against the development of hydrothorax/ascites and upper gastrointestinal bleeding after balloon-occluded retrograde transvenous obliteration (BRTO). Am J Gastroenterol. 2013;108:1612–9. 75. Kim DJ, Darcy MD, Mani NB, Park AW, Akinwande O, Ramaswamy RS, et al. Modified balloon-occluded retrograde transvenous obliteration (BRTO) techniques for the treatment of gastric varices: vascular plug-assisted retrograde transvenous obliteration (PARTO)/coil-assisted retrograde transvenous obliteration (CARTO)/balloon-occluded antegrade transvenous obliteration (BATO). Cardiovasc Intervent Radiol. 2018;41:835–47. 76. Kim YH, Kim YH, Kim CS, Kang UR, Kim SH, Kim JH. Comparison of balloon-occluded retrograde transvenous obliteration (BRTO) using ethanolamine oleate (EO), BRTO using sodium tetradecyl sulfate (STS) foam and vascular plugassisted retrograde transvenous obliteration (PARTO). Cardiovasc Intervent Radiol. 2016;39:840–6. 77. Kim T, Yang H, Lee CK, Kim GB. Vascular plug assisted retrograde transvenous obliteration (PARTO) for gastric varix bleeding patients in the emergent clinical setting. Yonsei Med J. 2016;57:973–9. 78. Gwon DI, Kim YH, Ko G-Y, Kim JW, Ko HK, Kim JH, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol. 2015;26: 1589–95. 79. Lunderquist A, Vang J. Transhepatic catheterization and obliteration of the coronary vein in patients with portal hypertension and esophageal varices. N Engl J Med. 1974;291: 646–9. 80. Saad WEA, Kitanosono T, Koizumi J. Balloon-occluded antegrade transvenous obliteration with or without balloonoccluded retrograde transvenous obliteration for the management of gastric varices: concept and technical applications. Tech Vasc Interv Radiol. 2012;15:203–25. 81. Chikamori F, Kuniyoshi N, Kawashima T, Shibuya S, Takase Y. Percutaneous transhepatic obliteration for isolated gastric varices with gastropericardiac shunt: case report. Abdom Imaging. 2006;31:249–52. 82. Kawai N, Minamiguchi H, Sato M, Ikoma A, Sanda H, Nakata K, et al. Percutaneous transportal outflow-vessel-occluded sclerotherapy for gastric varices unmanageable by balloonoccluded retrograde transvenous obliteration. Hepatol Res. 2013;43:430–5. 83. Arai H, Abe T, Takagi H, Mori M. Efficacy of balloon-occluded retrograde transvenous obliteration, percutaneous transhepatic obliteration and combined techniques for the management of gastric fundal varices. World J Gastroenterol. 2006;12: 3866–73. 84. Kiyosue H, Matsumoto S, Yamada Y, Hori Y, Okino Y, Okahara M, et al. Transportal intravariceal sclerotherapy with N-butyl-2- cyanoacrylate for gastric varices. J Vasc Interv Radiol. 2004;15: 505–9. 85. Uflacker R. Percutaneous transhepatic obliteration of gastroesophageal varices using absolute alcohol. Radiology. 1983; 146:621–5. 86. Tian X, Wang Q, Zhang C, Liu F, Cui Y, Liu F, et al. Modified percutaneous transhepatic variceal embolization with 2- octylcyanoacrylate for bleeding gastric varices: long-term follow-up outcomes. AJR Am J Roentgenol. 2011;197:502–9. 87. L’Herminé C, Chastanet P, Delemazure O, Bonnière PL, Durieu JP, Paris JC. Percutaneous transhepatic embolization of gastroesophageal varices: results in 400 patients. AJR Am J Roentgenol. 1989;152:755–60. 88. Wang G, Meng D, Huang G, Pei Q, Zhao L, Shi Y, et al. Balloonassisted percutaneous transhepatic antegrade embolization with 2-octyl cyanoacrylate for the treatment of isolated gastric varices with large gastrorenal shunts. BioMed Res Int. 2019;2019: 2674758. 89. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60. 90. Abraldes JG, Villanueva C, Bañares R, Aracil C, Catalina MV, García-Pagán JC, et al. for the Spanish Cooperative Group for Portal Hypertension and Variceal Bleeding. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2008;48:229–36. 91. Amitrano L, Guardascione MA, Manguso F, Bennato R, Bove A, DeNucci C, et al. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining shortterm prognosis and risk factors. Am J Gastroenterol. 2012;107: 1872–8. 92. Azoulay D, Castaing D, Majno P, Saliba F, Ichaï P, Smail A, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590–7. 93. Bañares R, Casado M, Rodríguez-Láiz JM, Camúñez F, Matilla A, Echenagusía A, et al. Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding. Am J Gastroenterol. 1998;93:75–9. 94. Sanyal AJ, Freedman AM, Luketic VA, Purdum PP, Shiffman ML, Tisnado J, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology. 1996;111:138–46. 95. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40: 793–801. 96. Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999;117:626–31. 97. Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data. Gastroenterology. 2021;160:193–205e10. 98. Dunne PDJ, Sinha R, Stanley AJ, Lachlan N, Ireland H, Shams A, et al. Randomised clinical trial: standard of care versus earlytransjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Aliment Pharmacol Ther. 2020;52:98–106. 99. Hussain I, Wong YJ, Lohan R, Lin S, Kumar R. Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials. J Gastroenterol Hepatol. 2022;37:455–63. 100. Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding (REACTAVB). NIHR. 2021. Accessed March 21, 2022. https://fundinga wards.nihr.ac.uk/award/NIHR130883